All patients
Age < 65y (younger) Age > 75y (older) Asian type ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (CPS < 1) PDL1 (CPS >1) PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TPS <50%) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mHNSCC - L2 - all population, immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 141, 2016 0.70 [0.51; 0.96]
EAGLE (D vs ICC), 2019 0.88 [0.72; 1.08]
EAGLE (DT vs ICC), 2019 1.04 [0.85; 1.27]
KEYNOTE-040 (all population), 2018 0.80 [0.65; 0.98]
0.87 [0.74 ; 1.01 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 46% 1,841 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 141, 2016 0.68 [0.54; 0.86]
0.68 [0.54 ; 0.86 ] CheckMate 141, 2016 1 0% 361 NA not evaluable PFS (extension)detailed results CheckMate 141, 2016 0.87 [0.68; 1.11]
0.87 [0.68 ; 1.11 ] CheckMate 141, 2016 1 0% 361 NA not evaluable progression or deaths (PFS)detailed results CheckMate 141, 2016 0.89 [0.70; 1.13]
EAGLE (D vs ICC), 2019 1.02 [0.84; 1.24]
EAGLE (DT vs ICC), 2019 1.09 [0.90; 1.33]
KEYNOTE-040 (all population), 2018 0.96 [0.79; 1.16]
1.00 [0.90 ; 1.10 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,841 moderate not evaluable DCRdetailed results EAGLE (D vs ICC), 2019 1.00 [0.63; 1.58]
EAGLE (DT vs ICC), 2019 1.12 [0.72; 1.75]
1.06 [0.77 ; 1.46 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 0% 985 moderate not evaluable objective responses (ORR)detailed results CheckMate 141, 2016 2.51 [1.07; 5.86]
EAGLE (D vs ICC), 2019 1.05 [0.66; 1.68]
EAGLE (DT vs ICC), 2019 1.07 [0.67; 1.70]
KEYNOTE-040 (all population), 2018 1.52 [0.88; 2.62]
1.29 [0.94 ; 1.77 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 26% 1,841 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 141, 2016 2.51 [1.07; 5.86]
2.51 [1.07 ; 5.86 ] CheckMate 141, 2016 1 0% 361 NA not evaluable AE (any grade)detailed results EAGLE (D vs ICC), 2019 0.45 [0.21; 0.94]
EAGLE (DT vs ICC), 2019 0.80 [0.35; 1.79]
0.58 [0.33 ; 1.02 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 6% 963 moderate not evaluable AE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.89 [0.62; 1.28]
EAGLE (DT vs ICC), 2019 1.33 [0.93; 1.90]
1.09 [0.74 ; 1.61 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 57% 963 moderate not evaluable AE leading to death (grade 5)detailed results EAGLE (D vs ICC), 2019 1.01 [0.52; 1.97]
EAGLE (DT vs ICC), 2019 1.32 [0.70; 2.46]
1.16 [0.74 ; 1.83 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 0% 963 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results EAGLE (D vs ICC), 2019 0.97 [0.53; 1.77]
EAGLE (DT vs ICC), 2019 1.54 [0.89; 2.68]
1.24 [0.79 ; 1.96 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 21% 963 moderate not evaluable SAE (any grade)detailed results EAGLE (D vs ICC), 2019 1.21 [0.80; 1.80]
EAGLE (DT vs ICC), 2019 1.39 [0.94; 2.06]
1.30 [0.98 ; 1.72 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 0% 963 moderate not evaluable STRAE (any grade)detailed results EAGLE (D vs ICC), 2019 1.16 [0.56; 2.38]
1.16 [0.56 ; 2.38 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable TRAE (any grade)detailed results CheckMate 141, 2016 0.31 [0.18; 0.52]
EAGLE (D vs ICC), 2019 0.29 [0.19; 0.45]
EAGLE (DT vs ICC), 2019 0.34 [0.22; 0.52]
KEYNOTE-040 (all population), 2018 0.33 [0.21; 0.51]
0.32 [0.26 ; 0.40 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.35 [0.21; 0.59]
EAGLE (DT vs ICC), 2019 0.61 [0.39; 0.96]
KEYNOTE-040 (all population), 2018 0.24 [0.15; 0.39]
0.38 [0.22 ; 0.65 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 74% 1,443 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 141, 2016 0.94 [0.08; 10.48]
EAGLE (D vs ICC), 2019 8.22 [0.43; 156.41]
EAGLE (DT vs ICC), 2019 3.93 [0.18; 87.52]
KEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57]
2.26 [0.70 ; 7.25 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 141, 2016 0.45 [0.18; 1.11]
EAGLE (D vs ICC), 2019 0.91 [0.36; 2.28]
EAGLE (DT vs ICC), 2019 0.97 [0.40; 2.39]
KEYNOTE-040 (all population), 2018 1.20 [0.55; 2.62]
0.86 [0.55 ; 1.32 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.28 [0.53; 3.10]
1.28 [0.53 ; 3.10 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
0.67 [0.06 ; 7.40 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.07 ; 12.36 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.98 [0.10 ; 9.44 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,443 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.06; 0.92]
EAGLE (D vs ICC), 2019 0.04 [0.00; 0.75]
EAGLE (DT vs ICC), 2019 0.34 [0.11; 1.10]
KEYNOTE-040 (all population), 2018 0.10 [0.01; 0.81]
0.22 [0.10 ; 0.47 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.02; 2.59]
EAGLE (D vs ICC), 2019 0.50 [0.05; 5.60]
EAGLE (DT vs ICC), 2019 2.47 [0.47; 12.85]
KEYNOTE-040 (all population), 2018 0.23 [0.03; 2.12]
0.63 [0.18 ; 2.16 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 26% 1,790 moderate not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.04 [0.01; 0.31]
0.04 [0.01 ; 0.31 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Cardiac disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.67 [0.04 ; 10.72 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.17 [0.01; 3.35]
EAGLE (DT vs ICC), 2019 0.65 [0.11; 3.91]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
0.58 [0.14 ; 2.36 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,443 moderate not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.99 [0.06 ; 15.94 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 0% 963 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
EAGLE (D vs ICC), 2019 0.17 [0.01; 3.35]
EAGLE (DT vs ICC), 2019 0.65 [0.11; 3.91]
KEYNOTE-040 (all population), 2018 3.85 [0.43; 34.71]
0.62 [0.14 ; 2.72 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 33% 1,790 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33]
3.83 [0.17 ; 85.33 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.34 [0.12 ; 14.83 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Epistaxis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.78 [0.18; 3.32]
EAGLE (D vs ICC), 2019 1.01 [0.14; 7.25]
EAGLE (DT vs ICC), 2019 1.47 [0.24; 8.87]
KEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57]
1.18 [0.50 ; 2.75 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.05 [0.00; 0.79]
0.05 [0.00 ; 0.79 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Gastritis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.23 [0.02; 2.59]
KEYNOTE-040 (all population), 2018 0.35 [0.14; 0.86]
0.33 [0.14 ; 0.77 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.57 [0.23; 1.40]
0.57 [0.23 ; 1.40 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 2.01 [0.07; 60.26]
2.01 [0.07 ; 60.26 ] KEYNOTE-040 (all population), 2018 1 0% 495 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.94 [0.08; 10.48]
KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.94 [0.15 ; 5.84 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.43 [0.03 ; 5.58 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.67 [0.04 ; 10.72 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
0.94 [0.03 ; 28.25 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.02 [0.15 ; 6.73 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.31 [0.03; 3.04]
0.35 [0.05 ; 2.48 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.03; 7.55]
EAGLE (D vs ICC), 2019 1.01 [0.06; 16.29]
EAGLE (DT vs ICC), 2019 0.49 [0.02; 14.58]
KEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15]
0.45 [0.10 ; 1.98 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 141, 2016 3.81 [0.20; 72.71]
3.81 [0.20 ; 72.71 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.54 [0.06 ; 4.66 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.08 [0.00; 1.54]
EAGLE (D vs ICC), 2019 0.12 [0.01; 2.37]
EAGLE (DT vs ICC), 2019 0.12 [0.01; 2.29]
KEYNOTE-040 (all population), 2018 0.07 [0.00; 1.17]
0.09 [0.02 ; 0.40 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.04 ; 6.17 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.40 [0.10; 1.57]
0.40 [0.10 ; 1.57 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.51 [0.02; 15.13]
EAGLE (DT vs ICC), 2019 0.49 [0.02; 14.58]
KEYNOTE-040 (all population), 2018 0.19 [0.02; 1.61]
0.29 [0.06 ; 1.44 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,443 moderate not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
EAGLE (D vs ICC), 2019 2.03 [0.07; 60.79]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.67 [0.12 ; 3.87 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.04; 5.26]
0.47 [0.04 ; 5.26 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.04 [0.00; 0.68]
EAGLE (DT vs ICC), 2019 0.08 [0.01; 0.60]
KEYNOTE-040 (all population), 2018 0.04 [0.01; 0.33]
0.05 [0.01 ; 0.19 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,443 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.43 [0.03 ; 5.58 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15]
0.16 [0.01 ; 3.15 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.50 [0.05; 5.60]
EAGLE (DT vs ICC), 2019 0.24 [0.01; 5.40]
0.38 [0.06 ; 2.57 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019 2 0% 963 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 1.89 [0.08; 42.24]
KEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33]
2.69 [0.30 ; 24.18 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
KEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27]
0.51 [0.08 ; 3.20 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 0% 1,790 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.26 [0.02 ; 2.98 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Rash TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.97 [0.14 ; 6.92 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,443 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.05 [0.08 ; 13.66 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 1.89 [0.08; 42.24]
KEYNOTE-040 (all population), 2018 1.44 [0.40; 5.16]
1.50 [0.46 ; 4.88 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27]
0.24 [0.01 ; 5.27 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.54 [0.15; 1.86]
0.54 [0.15 ; 1.86 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
KEYNOTE-040 (all population), 2018 0.31 [0.08; 1.15]
0.27 [0.08 ; 0.89 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.67 [0.04 ; 10.72 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 2.03 [0.07; 60.79]
EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
KEYNOTE-040 (all population), 2018 0.08 [0.01; 0.65]
0.35 [0.04 ; 2.92 ] EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 34% 1,443 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
EAGLE (D vs ICC), 2019 1.01 [0.06; 16.29]
EAGLE (DT vs ICC), 2019 1.96 [0.18; 21.75]
KEYNOTE-040 (all population), 2018 0.09 [0.01; 1.72]
0.46 [0.10 ; 2.11 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, EAGLE (DT vs ICC), 2019, KEYNOTE-040 (all population), 2018 4 17% 1,790 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Vascular disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Rash AE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 10:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 101
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743